Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03005288 · ClinicalTrials.gov registry record · Phase 2
Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
A Phase 2 study of Diabetes Mellitus, Type 2, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
- 9
- Study locations
NCT03005288 is a Phase 2 study of Diabetes Mellitus, Type 2 that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 78 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower). The trial reports 9 study locations across 5 states.
The verdict
NCT03005288, a Phase 2 study of Diabetes Mellitus, Type 2, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
- 9
- Study locations
Study Summary
This study assessed the safety, pharmacokinetics and efficacy of bimagrumab when administered in overweight and obese patients with type 2 diabetes
Conditions Studied
Interventions
- OTHER Placebo
- DRUG BYM338 10 mg/kg
Study Locations (9)
Florida
- Novartis Investigative Site - Miami
- Novartis Investigative Site - Miami
- Novartis Investigative Site - Miami Lakes
- Novartis Investigative Site - Orlando
New Jersey
- Novartis Investigative Site - Berlin
- Novartis Investigative Site - Eatontown
California
- Novartis Investigative Site - Anaheim
Louisiana
- Novartis Investigative Site - Baton Rouge
Mid Glamorgan
- Novartis Investigative Site - Merthyr Tydfil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2017-02-01 |
| Est. Completion | 2019-05-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03005288
The ClinicalTrials.gov registry entry for NCT03005288 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03005288 reports 9 study locations spanning 5 distinct geographic areas - top geographies include Florida, New Jersey, California.
Frequently Asked Questions
What is clinical trial NCT03005288 about?
NCT03005288 is a clinical study titled "Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes". This study assessed the safety, pharmacokinetics and efficacy of bimagrumab when administered in overweight and obese patients with type 2 diabetes
What is the current status of trial NCT03005288?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2017-02-01. Estimated completion is 2019-05-08.
What conditions does trial NCT03005288 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT03005288?
The interventions under investigation include: Placebo (OTHER), BYM338 10 mg/kg (DRUG).
Who is sponsoring clinical trial NCT03005288?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03005288 being conducted?
This trial has 9 study locations across California, Florida, Louisiana, New Jersey, Mid Glamorgan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DETERMINE: Detemir vs NPH
RECRUITING · Phase 2
-
MANAGe-DM: Novel Nurse Case Management to Improve Diabetes Outcomes in Formerly Incarcerated Black Men
RECRUITING · Phase 2
-
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
RECRUITING · Phase 2
-
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
RECRUITING · Phase 2
-
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Addressing Basic Needs to Improve Diabetes Outcomes in Medicaid Beneficiaries
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.